MCID: INT007
MIFTS: 54

Intermediate Coronary Syndrome

Categories: Cardiovascular diseases

Aliases & Classifications for Intermediate Coronary Syndrome

MalaCards integrated aliases for Intermediate Coronary Syndrome:

Name: Intermediate Coronary Syndrome 12 15 17
Unstable Angina 12 15 32
Angina, Unstable 44 71
Myocardial Preinfarction Syndrome 71
Anginal Chest Pain at Rest 12
Impending Infarction 12
Preinfarction Angina 12
Worsening Angina 12
Angina at Rest 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8805
ICD9CM 34 411.1
MeSH 44 D000789
NCIt 50 C66911
SNOMED-CT 67 155308009
ICD10 32 I20.0
UMLS 71 C0002965 C0086666

Summaries for Intermediate Coronary Syndrome

MalaCards based summary : Intermediate Coronary Syndrome, also known as unstable angina, is related to coronary heart disease 1 and coronary thrombosis, and has symptoms including angina pectoris An important gene associated with Intermediate Coronary Syndrome is PF4 (Platelet Factor 4), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Folate Metabolism. The drugs Nicorandil and Fondaparinux have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Intermediate Coronary Syndrome

Diseases related to Intermediate Coronary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 476)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 32.1 PCSK9 INS CRP APOB ACE
2 coronary thrombosis 31.2 SERPINC1 SELP P2RY12 ITGA2B F3 CRP
3 proteasome-associated autoinflammatory syndrome 1 31.0 SELP INS IL6 CRP
4 coronary artery vasospasm 31.0 TNNI3 CRP ACE
5 thrombophilia due to thrombin defect 30.9 SERPINC1 PF4 F3
6 mitral valve insufficiency 30.9 TNNT2 TNNI3 MIR423 CRP ACE
7 aortic aneurysm 30.8 MIR145 IL6 CRP ACE
8 heparin-induced thrombocytopenia 30.7 SERPINC1 PF4 F3
9 subclavian steal syndrome 30.7 F3 CRP
10 pulmonary edema 30.7 TNNT2 TNNI3 SERPINC1 CRP ACE
11 mental depression 30.7 INS IL6 CRP
12 thrombosis 30.6 SERPINC1 SELP PF4 P2RY12 ITGA2B F3
13 carotid stenosis 30.6 SELP CRP ACE
14 heart valve disease 30.6 TNNI3 MIR423 MIR126 CRP ACE
15 cardiac tamponade 30.6 TNNI3 F3 CRP ACE
16 aortic aneurysm, familial abdominal, 1 30.6 SERPINC1 MIR126 IL6 CRP ACE
17 aortic dissection 30.5 TNNT2 IL6 CRP ACE
18 urinary tract infection 30.5 CRP ACE
19 femoral neuropathy 30.4 MB F3
20 congestive heart failure 30.4 TNNT2 TNNI3 INS IL6 CRP ACE
21 hypercholesterolemia, familial, 1 30.4 PCSK9 INS CRP APOB ACE
22 pericarditis 30.4 TNNT2 TNNI3 IL6 CRP ACE
23 myocardial stunning 30.4 TNNT2 TNNI3 SERPINC1 ACE
24 systolic heart failure 30.4 IL6 CRP ACE
25 thrombophlebitis 30.3 SERPINC1 F3 CRP
26 mitral valve stenosis 30.3 SERPINC1 SELP PF4 F3 CRP ACE
27 aortic valve insufficiency 30.3 TNNI3 F3 CRP ACE
28 inferior myocardial infarction 30.3 TNNI3 ACE
29 thrombocytopenia 30.3 SERPINC1 SELP PF4 P2RY12 ITGA2B IL6
30 atrial fibrillation 30.3 SELP PF4 CRP ACE
31 lung disease 30.3 INS IL6 F3 CRP ACE
32 peripheral vascular disease 30.3 SERPINC1 SELP PF4 IL6 F3 CRP
33 background diabetic retinopathy 30.3 INS IL6 CRP ACE
34 bernard-soulier syndrome 30.2 SELP P2RY12 ITGA2B F3
35 kawasaki disease 30.2 MIR145 IL6 CRP
36 familial hyperlipidemia 30.2 INS CRP APOB ACE
37 gas gangrene 30.2 TNNT2 TNNT1 TNNI3 MB IL6 CRP
38 toxic shock syndrome 30.2 SERPINC1 IL6 F3 CRP
39 left bundle branch hemiblock 30.2 TNNT2 TNNT1 TNNI3 P2RY12 ITGA2B CRP
40 thrombophilia 30.2 SERPINC1 SELP PF4 F3
41 lipid metabolism disorder 30.2 MIR126 INS IL6 CRP APOB ACE
42 hyperuricemia 30.2 INS CRP APOB
43 essential thrombocythemia 30.2 SERPINC1 SELP PF4 ITGA2B IL6 F3
44 thrombocytosis 30.2 SERPINC1 SELP PF4 IL6 F3 CRP
45 endocarditis 30.1 TNNI3 SERPINC1 PF4 IL6 CRP
46 angina pectoris 30.1 TNNI3 MB INS IL6 F3 CRP
47 antiphospholipid syndrome 30.1 SERPINC1 SELP PF4 F3 CRP
48 cholangitis 30.1 IL6 F3 CRP
49 migraine with or without aura 1 30.1 INS IL6 CRP ACE
50 microvascular complications of diabetes 1 30.1 SELP MIR423 INS

Comorbidity relations with Intermediate Coronary Syndrome via Phenotypic Disease Network (PDN): (show top 50) (show all 101)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Stress Disorder
Allergic Urticaria Angina Pectoris
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Asbestosis Atrioventricular Block
Atrophic Gastritis Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bleeding Disorder, Platelet-Type, 11 Bronchitis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebrovascular Disease
Chronic Intestinal Vascular Insufficiency Constrictive Pericarditis
Coronary Artery Aneurysm Deficiency Anemia
Diabetic Polyneuropathy Diaphragm Disease
Dressler's Syndrome Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gallbladder Disease
Gastroesophageal Reflux Generalized Atherosclerosis
Gout Heart Disease
Hemopericardium Hyperlipoproteinemia, Type I
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hypertension, Essential Hypertensive Encephalopathy

Graphical network of the top 20 diseases related to Intermediate Coronary Syndrome:



Diseases related to Intermediate Coronary Syndrome

Symptoms & Phenotypes for Intermediate Coronary Syndrome

UMLS symptoms related to Intermediate Coronary Syndrome:


angina pectoris

MGI Mouse Phenotypes related to Intermediate Coronary Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 ACE APOB CRP F3 IL6 INS
2 homeostasis/metabolism MP:0005376 9.8 ACE APOB CRP F3 IL6 INS
3 muscle MP:0005369 9.28 APOB F3 IL6 INS MB SERPINC1

Drugs & Therapeutics for Intermediate Coronary Syndrome

Drugs for Intermediate Coronary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Fondaparinux Approved, Investigational Phase 4 104993-28-4
3
Abciximab Approved Phase 4 143653-53-6
4
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Chromium Approved Phase 4 7440-47-3 27668
8
Adenosine Approved, Investigational Phase 4 58-61-7 60961
9
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Cangrelor Approved Phase 4 163706-06-7 9854012
13
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
14
Metformin Approved Phase 4 657-24-9 14219 4091
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
17
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
18
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
21
Atorvastatin Approved Phase 4 134523-00-5 60823
22
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
23
Trimetazidine Approved, Investigational Phase 4 5011-34-7
24
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
25
Nitric Oxide Approved Phase 4 10102-43-9 145068
26
Ticagrelor Approved Phase 4 274693-27-5 9871419
27
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
28
Dalteparin Approved Phase 4 9005-49-6
29
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
30
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32 Fibrinolytic Agents Phase 4
33 Angelica Phase 4
34 Calamus Phase 4
35 Vitamin B Complex Phase 4
36 Folate Phase 4
37 Vitamin B9 Phase 4
38 PENTA Phase 4
39 Hormone Antagonists Phase 4
40 Hormones Phase 4
41 polysaccharide-K Phase 4
42 Chinese Salvia Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Eicosapentaenoic acid ethyl ester Phase 4
45 Narcotic Antagonists Phase 4
46 Dopamine Agents Phase 4
47 Gastrointestinal Agents Phase 4
48 Dopamine Antagonists Phase 4
49 Antiemetics Phase 4
50 Dipeptidyl-Peptidase IV Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 236)
# Name Status NCT ID Phase Drugs
1 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
2 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
3 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
4 A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Efficacy and Safety of Low Dose Ticagrelor Compared With Standard Dose Ticagrelor in Patients With Unstable Angina Pectoris After Drug Eluting Stent Implantation Unknown status NCT03620760 Phase 4 Ticagrelor 90 mg;Ticagrelor 45 mg;Aspirin
5 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
6 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
7 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
8 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
9 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
10 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
11 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
12 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
13 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
14 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
15 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
16 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
17 A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris Completed NCT02007187 Phase 4 Danhong injection;Placebo
18 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
19 The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study Completed NCT02612116 Phase 4 Pulverized ticagrelor sublingually;Pulverized ticagrelor orally;Integral ticagrelor
20 Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome. Completed NCT00276432 Phase 4
21 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone - a Randomized Study Completed NCT02939248 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,naloxone
22 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine Alone - a Randomized Study Completed NCT02939235 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,metoclopramide
23 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
24 FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8) Completed NCT00790907 Phase 4 fondaparinux background and standard dose UFH;Fondaparinux background and low dose heparin;Open label fondaparinux
25 A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS) Completed NCT00327418 Phase 4 Atorvastatin
26 Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) - a Randomized Study Comparing a First-Generation With a Second-Generation Stent. Completed NCT00139802 Phase 4
27 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
28 The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT) Completed NCT01331967 Phase 4 Pioglitazone
29 Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI) Completed NCT01293097 Phase 4 Atorvastatin;Statin
30 The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial Completed NCT02733341 Phase 4 Cangrelor;Ticagrelor
31 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
32 Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease Completed NCT00181818 Phase 4 bupropion SR (sustained-release)
33 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2) Completed NCT00133003 Phase 4 Abciximab;Placebo
34 Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent Completed NCT01826552 Phase 4
35 A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry. Completed NCT01895751 Phase 4
36 Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation Completed NCT00905671 Phase 4
37 Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up. Completed NCT01637012 Phase 4
38 Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial Recruiting NCT03980990 Phase 4 Metformin
39 Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris - METHANE Study Recruiting NCT04442919 Phase 4 Ticagrelor followed with Methoxyflurane;Ticagrelor followed with Morphine;Ticagrelor alone
40 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial Recruiting NCT02601157 Phase 4 3-months DAPT;1-year DAPT
41 Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive Indication Active, not recruiting NCT02618837 Phase 4
42 Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial Active, not recruiting NCT03363035 Phase 4 Rivaroxaban 2.5 mg;Rivaroxaban 5 mg;Enoxaparin
43 Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Following Percutaneous Coronary Intervention (PCI) Active, not recruiting NCT04090281 Phase 4
44 Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial Not yet recruiting NCT04661709 Phase 4 Wen Xin granule;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Aspirin Enteric-coated Tablets;WXG placebo;Trimetazidine Dihydrochloride Tablets;glyceryl trinitrate
45 A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities Terminated NCT00518245 Phase 4 enoxaparin
46 Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy Terminated NCT00435487 Phase 4 Dalteparin ( Fragmin);Unfractionated heparin
47 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Terminated NCT02037412 Phase 4 Ticagrelor;Clopidogrel
48 A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR) Terminated NCT01204320 Phase 4
49 A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI) Terminated NCT02000661 Phase 4
50 Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients Withdrawn NCT00337116 Phase 4 iso sorbide dinitrate iv bolus or s/l

Search NIH Clinical Center for Intermediate Coronary Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 51 :


abciximab
bivalirudin
Dalteparin
Dalteparin Sodium
Enoxaparin
eptifibatide
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
lepirudin
tirofiban
TIROFIBAN HYDROCHLORIDE

Cochrane evidence based reviews: angina, unstable

Genetic Tests for Intermediate Coronary Syndrome

Anatomical Context for Intermediate Coronary Syndrome

MalaCards organs/tissues related to Intermediate Coronary Syndrome:

40
Endothelial, Heart, Kidney, Neutrophil, Monocytes, Whole Blood, Brain

Publications for Intermediate Coronary Syndrome

Articles related to Intermediate Coronary Syndrome:

(show top 50) (show all 13152)
# Title Authors PMID Year
1
Association Between Plasma ADAMTS-9 Levels and Severity of Coronary Artery Disease. 61
33307720 2021
2
Differential Vascular Responses to New-Generation Drug-Eluting Stenting According to Clinical Presentation: Three-Month Optical Coherence Tomographic Study. 61
33342226 2021
3
Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. 61
31350011 2021
4
Impact of Age on Gender Difference in Long-term Outcome of Patients With Acute Myocardial Infarction (from J-MINUET). 61
33279486 2021
5
Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. 61
33186669 2021
6
Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review). 61
33603870 2021
7
Trace element, immune and opioid biomarkers of unstable angina, increased atherogenicity and insulin resistance: Results of machine learning. 61
33338984 2021
8
Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. 61
33285089 2021
9
Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. 61
32472526 2021
10
Brugada phenocopy in a patient with unstable angina and three-vessel coronary artery disease. 61
33586167 2021
11
Effect of Yugengtongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial. 61
33259734 2021
12
The relationship between carotid and coronary calcification in patients with coronary artery disease. 61
33583121 2021
13
Comparison of Patients With Nonobstructive Coronary Artery Disease With Versus Without Myocardial Infarction (from the VA Clinical Assessment Reporting and Tracking [CART] Program). 61
33539858 2021
14
Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. 61
33220321 2021
15
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction. 61
33602439 2021
16
CD100 modulates cytotoxicity of CD8+ T cells in patients with acute myocardial infarction. 61
33593275 2021
17
Optimization of GRACE Risk Stratification by N-Terminal Pro-B-type Natriuretic Peptide Combined With D-Dimer in Patients With Non-ST-Elevation Myocardial Infarction. 61
33159905 2021
18
Absence of coronary angioscopy-derived in-stent thrombi is associated with major bleeding events in acute myocardial infarction. 61
33486352 2021
19
microRNA neural networks improve diagnosis of acute coronary syndrome (ACS). 61
32305360 2021
20
Coronary angiography-derived contrast fractional flow reserve. 61
33590679 2021
21
Interleukin-9-secreting CD4+ T cells regulate CD8+ T cells cytotoxicity in patients with acute coronary syndromes. 61
33113251 2021
22
Comparison of Prevalence, Presentation, and Prognosis of Acute Coronary Syndromes in ≤35 years, 36 - 54 years, and ≥ 55 years Patients. 61
33166493 2021
23
Is gender a risk factor for bilateral internal thoracic artery grafting? A twenty-year follow-up. 61
33314278 2021
24
Healed Erosion: The Role of Pre-interventional Optical Coherence Tomography in a Patient Clinically Suspected of Having Unstable Angina with Coronary Spasm. 61
33583890 2021
25
The effect of ticagrelor on microarterial thrombosis in an experimental model. 61
33593206 2021
26
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. 61
33516690 2021
27
Morphology and phenotype characteristics of atherosclerotic plaque in patients with acute coronary syndrome: contemporary optical coherence tomography findings. 61
33587362 2021
28
The epidemiology of acute coronary syndromes in French Guiana. 61
33067006 2021
29
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). 61
32336695 2021
30
Vitamin D and Its Role in the Lipid Metabolism and the Development of Atherosclerosis. 61
33572397 2021
31
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. 61
33546739 2021
32
Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. 61
33331883 2021
33
Trajectory of Cardiac Catheterization for Acute Coronary Syndrome and Out-of-Hospital Cardiac Arrest During the COVID-19 Pandemic. 61
33447325 2021
34
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. 61
32785614 2021
35
Prognostic Impacts of Comorbid Significant Coronary Stenosis and Coronary Artery Spasm in Patients With Stable Coronary Artery Disease. 61
33455423 2021
36
Predictive Inflammation-related microRNAs for Cardiovascular Events Following Early-Onset Coronary Artery Disease. 61
33261889 2021
37
High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study. 61
33431716 2021
38
Echolucency of carotid plaque is useful for selecting high-risk patients with chronic coronary artery disease who benefit from intensive lipid-lowering therapy. 61
33500186 2021
39
Validity of TIMI Score for Predicting 14-Day Mortality of Non-ST Elevation Myocardial Infarction Patients. 61
33564522 2021
40
Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance. 61
33462090 2021
41
Trends Over Time in the Incidences of ST-Segment Elevation Myocardial Infarction and Non-ST-Segment Elevation Myocardial Infarction During the Past Decade in a Rural Japanese High-Aged Population. 61
33441496 2021
42
Platelet-fibrin clot strength measured by thromboelastography could predict hypercoagulability and antiplatelet effects in patients after percutaneous coronary intervention. 61
33440968 2021
43
Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. 61
33438437 2021
44
Pro-inflammatory Mediators and Oxidative Stress: Therapeutic Markers for Recurrent Angina Pectoris after Coronary Artery Stenting in Elderly Patients. 61
33511935 2021
45
Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions. 61
32859455 2021
46
Aortic Arch Replacement without Deep Hypothermic Circulatory Arrest. 61
33505758 2021
47
One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. 61
33515411 2021
48
Genetic Polymorphism of Angiotensin II Type 1 Receptors and Their Effect on the Clinical Outcome of Captopril Treatment in Arab Iraqi Patients with Acute Coronary Syndrome (Mid Euphrates). 61
33505131 2021
49
Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome. 61
32578166 2021
50
Outcome of patients with prior coronary bypass surgery admitted with an acute coronary syndrome. 61
33462121 2021

Variations for Intermediate Coronary Syndrome

Expression for Intermediate Coronary Syndrome

Search GEO for disease gene expression data for Intermediate Coronary Syndrome.

Pathways for Intermediate Coronary Syndrome

GO Terms for Intermediate Coronary Syndrome

Cellular components related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 SERPINC1 PF4 PCSK9 INS IL6 F3
2 endoplasmic reticulum lumen GO:0005788 9.65 SERPINC1 PCSK9 INS IL6 APOB
3 extracellular space GO:0005615 9.44 SERPINC1 SELP PF4 PCSK9 MIR423 MIR342
4 cardiac myofibril GO:0097512 9.32 TNNT2 TNNI3
5 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3
6 troponin complex GO:0005861 9.13 TNNT2 TNNT1 TNNI3

Biological processes related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.73 P2RY12 MIR126 INS F3
2 positive regulation of gene expression GO:0010628 9.73 PF4 INS IL6 F3 CRP APOB
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 SELP MIR126 INS
4 hemostasis GO:0007599 9.58 SERPINC1 P2RY12 F3
5 acute-phase response GO:0006953 9.54 INS IL6 CRP
6 positive regulation of leukocyte migration GO:0002687 9.51 SELP ITGA2B
7 muscle filament sliding GO:0030049 9.5 TNNT2 TNNT1 TNNI3
8 negative regulation of ATPase activity GO:0032780 9.49 TNNT2 TNNI3
9 neutrophil mediated immunity GO:0002446 9.48 IL6 ACE
10 negative regulation of lipid storage GO:0010888 9.46 IL6 CRP
11 cellular protein metabolic process GO:0044267 9.35 SERPINC1 PCSK9 INS IL6 APOB
12 slow-twitch skeletal muscle fiber contraction GO:0031444 9.16 TNNT1 MB
13 regulation of muscle contraction GO:0006937 8.8 TNNT2 TNNT1 TNNI3

Molecular functions related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.56 SERPINC1 SELP PF4 APOB
2 troponin T binding GO:0031014 9.16 TNNT1 TNNI3
3 troponin C binding GO:0030172 8.96 TNNT2 TNNI3
4 low-density lipoprotein particle receptor binding GO:0050750 8.8 PCSK9 CRP APOB

Sources for Intermediate Coronary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....